Legend Biotech's 15min Chart Sees MACD & KDJ Death Cross
PorAinvest
miércoles, 20 de agosto de 2025, 10:22 am ET1 min de lectura
LEGN--
Santos brings a wealth of financial leadership experience to Legend Biotech. At AstraZeneca, he served as CFO for U.S. oncology and previously held the position of acting area vice president for Latin America. His compensation package includes a base salary of $500,000, with a potential annual bonus worth 45% of his salary. Starting in 2026, Santos can receive an annual stock grant anticipated to be worth at least $1 million [1].
Technical indicators, such as the MACD Death Cross and the KDJ Death Cross, have recently been triggered on Legend Biotech's 15-minute chart, as of August 20, 2025, at 10:15. These indicators suggest a potential continuation of the downward trend in the stock price, with momentum shifting in favor of a further decrease [2].
References:
[1] https://www.marketscreener.com/news/legend-biotech-taps-astrazeneca-executive-for-cfo-ce7c51dcd98efe21
[2] https://www.marketscreener.com/news/legend-biotech-15-minute-chart-triggers-macd-and-kdj-death-crosses-august-20-2025-1015
Legend Biotech's 15-minute chart has recently triggered a MACD Death Cross and a KDJ Death Cross, as of August 20, 2025, at 10:15. This indicates a potential continuation of the downward trend in the stock price, with momentum shifting in favor of a further decrease.
Legend Biotech has appointed Carlos Santos as its new Chief Financial Officer (CFO), effective immediately. Santos, a seasoned executive with extensive experience at AstraZeneca, Alcon, and Intel, will succeed Jessie Yeung, who served as interim CFO since January [1]. Santos' appointment comes as the company's stock has been showing signs of a downward trend, as indicated by recent technical indicators.Santos brings a wealth of financial leadership experience to Legend Biotech. At AstraZeneca, he served as CFO for U.S. oncology and previously held the position of acting area vice president for Latin America. His compensation package includes a base salary of $500,000, with a potential annual bonus worth 45% of his salary. Starting in 2026, Santos can receive an annual stock grant anticipated to be worth at least $1 million [1].
Technical indicators, such as the MACD Death Cross and the KDJ Death Cross, have recently been triggered on Legend Biotech's 15-minute chart, as of August 20, 2025, at 10:15. These indicators suggest a potential continuation of the downward trend in the stock price, with momentum shifting in favor of a further decrease [2].
References:
[1] https://www.marketscreener.com/news/legend-biotech-taps-astrazeneca-executive-for-cfo-ce7c51dcd98efe21
[2] https://www.marketscreener.com/news/legend-biotech-15-minute-chart-triggers-macd-and-kdj-death-crosses-august-20-2025-1015
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios